Roche snaps up ex-US rights to Sarepta's DMD gene therapy

Roche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar deal.

Solid Bio hit as FDA slaps clinical hold on DMD gene therapy

Roche joins others in dropping myostatin inhibitor for DMD

NS Pharma steals a march on Sarepta with DMD drug

FDA says no to Sarepta's golodirsen, blocking bid to expand ...

Sarepta DMD gene therapy could improve patients' motor funct...

Sarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase 1 trial showing an improvement in patients’